Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy.
Ocular neovascularization (NV) is the primary cause of blindness in a wide range of ocular diseases, such as diabetic retinopathy (DR) and age-related macular degeneration (AMD). The exact mechanism underlying the pathogenesis of ocular NV is not yet well understood, and as a consequence, there is no satisfactory therapy for ocular NV. In the last 10 years, a number of studies provided increasing evidence demonstrating that the imbalance between angiogenic stimulating factors and angiogenic inhibitors is a major contributor to the angiogenesis induced by various insults, such as hypoxia or ischemia, inflammation and tumor. The angiogenic inhibitors alone or in combination with other existing therapies are, therefore, believed to be promising in the treatment of ocular NV in the near future. This article reviews recent progress in studies on the mechanisms and treatment of ocular NV, focusing on the implication and therapeutic potential of endogenous angiogenic inhibitors in ocular NV.
Zhang
Sarah X
SX
Department of Medicine Endocrinology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Ma
Jian-xing
JX
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000378:metabolism; D016510:Corneal Neovascularization / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D011379:Prognosis; D015861:Retinal Neovascularization / Q000188:drug therapy* / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000502:physiology*
D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A